ANVIA
Anvia Therapeutics is developing small molecule inhibitors against clinically validated targets to expand treatment options for patients suffering from inflammatory and autoimmune diseases.
Overview
Anvia Therapeutics is developing small molecule inhibitors against clinically validated targets to expand treatment options for patients suffering from inflammatory and autoimmune diseases.
ANVIA's Mission
Molecular glues are small molecules that can modify protein structure to alter function. The Tumor Necrosis Factor superfamily (TNFSF) is a group of signaling proteins involved in regulating immune responses and mediating inflammation and autoimmune diseases. Anvia is advancing the rational design and development of molecular glues that target TNFSF ligands to deliver biologic-like efficacy in inflammatory and autoimmune diseases.
